BCYC — Bicycle Therapeutics Balance Sheet
0.000.00%
- $644.06m
- -$147.93m
- $35.28m
- 60
- 20
- 17
- 23
Annual balance sheet for Bicycle Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 136 | 439 | 339 | 526 | 880 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 14.6 | 11.9 | 21.2 | 24 | 35.7 |
Prepaid Expenses | |||||
Total Current Assets | 156 | 459 | 369 | 562 | 929 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.61 | 17.8 | 32.8 | 27.7 | 17.2 |
Other Long Term Assets | |||||
Total Assets | 161 | 480 | 411 | 595 | 957 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 23.1 | 36.2 | 53.3 | 69.5 | 67.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 65.7 | 134 | 140 | 224 | 164 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 95.5 | 346 | 271 | 371 | 793 |
Total Liabilities & Shareholders' Equity | 161 | 480 | 411 | 595 | 957 |
Total Common Shares Outstanding |